Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRACR2A | Q9BSW2 | 5/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6608859 | 0.95 | CRACR2A (0.46) | CRACR2ANAMPTNAAALMNASTAT3 | |
| SCHEMBL6617757 | 0.91 | CRACR2A (0.45) | CRACR2ANAMPTKDM4EMEN1POLB | |
| SCHEMBL6607134 | 0.89 | MAPT (0.43) | NAMPTKDM4EMEN1POLBKMT2A | |
| SCHEMBL6617307 | 0.86 | CRACR2A (0.44) | CRACR2ANAMPTKDM4EMEN1POLB | |
| SCHEMBL6617319 | 0.85 | RAB9A (0.40) | CRACR2ANAMPTKDM4EMEN1KMT2A | |
| SCHEMBL6610153 | 0.84 | MEN1 (0.41) | CRACR2ANAMPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6613875 | 0.82 | RAB9A (0.47) | KDM4EMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6615036 | 0.82 | MAPT (0.47) | KDM4EMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6621026 | 0.82 | CRACR2A (0.46) | CRACR2AKDM4EMEN1POLBKMT2A | |
| SCHEMBL6617672 | 0.81 | CRACR2A (0.47) | CRACR2AKDM4EMEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458379-A1 | HYDROXYPHENYL-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2004-09-22 | — | — | EP | claimed |
| US-20040010027-A1 | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them | PHARMACIA & UPJOHN SPA (IT) | 2004-01-15 | — | — | US | claimed |
| WO-2003051358-A1 | HYDROXYPHENYL-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA SPA (IT) | 2003-06-26 | — | — | WO | claimed |
| EP-1458379-A1 | HYDROXYPHENYL-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2004-09-22 | — | — | EP | disclosed |
| US-20040010027-A1 | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them | PHARMACIA & UPJOHN SPA (IT) | 2004-01-15 | — | — | US | disclosed |
| WO-2003051358-A1 | HYDROXYPHENYL-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA SPA (IT) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010027-A1 | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them | CNKSR1, CSNK1A1, CDK6 | CRACR2A 437/4885NAMPT 2586/4885KDM4E 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.